cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.5127076
title: Supplementary Material for: Welche Risiken und Nebenwirkungen hat Psychotherapie? - Entwicklung des Inventars zur Erfassung Negativer Effekte von Psychotherapie (INEP)

description: <b><i>Hintergrund: </i></b>Negative Effekte von Psychotherapie sind bis heute wenig systematisch untersucht. Diese Studie stellt die Konstruktion eines Selbstbeurteilungsverfahrens zur Erfassung negativer Effekte von Psychotherapie vor. <b><i>Patienten und Methoden: </i></b>Ein Itempool zur breiten Erfassung möglicher erlebter negativer Veränderungen durch Psychotherapie in den Bereichen intrapersonelle Veränderungen, Partnerschaft, Freunde und Familie, Arbeitsplatz, therapeutisches Fehlverhalten und Stigmatisierung wurde über Literaturrecherchen und Expertenbefragungen generiert. Items wurden bipolar formuliert, um ein negatives Priming zu verhindern. Zusätzlich wurde die jeweilige Attribution der Veränderung auf die Psychotherapie oder andere externe Ursachen erfragt. Im Zeitraum von November 2010 bis Februar 2011 nahmen 195 ehemalige Psychotherapiepatienten (74,9% weiblich; Alter M = 38,4 Jahre; SD = 11,8) an einer Onlineuntersuchung teil, bei der auch die Rahmenbedingungen der Psychotherapie erfragt wurden. <b><i>Ergebnisse: </i></b>Von 195 Befragten gaben 93,8% (n = 183) an, negative Effekte durch ihre Psychotherapie erlebt zu haben. Die höchsten Raten erlebter negativer Effekte ergaben sich in den Bereichen intrapersonelle Veränderungen (15,8%), Stigmatisierung (14,9%) und Partnerschaft (12,0%). Schwerwiegendes therapeutisches Fehlverhalten wie sexuelle Belästigung (2,6%) oder körperliche Gewalt (1%) durch den Therapeuten hatten eine geringe Prävalenz. Anhand von Itemanalysen sowie inhaltlichen Kriterien wurde das Inventar zur Erfassung negativer Effekte von Psychotherapie (INEP) mit 21 Items erstellt (α = 0,86). <b><i>Diskussion: </i></b>Ein Großteil der negativen Veränderungen trat innerhalb des therapeutischen Settings auf (z.B. verletzende Aussagen des Therapeuten, Phasen der Niedergeschlagenheit). Zudem wurden mehr negative Effekte genannt, wenn die therapeutische Beziehung als negativ beschrieben wurde. <b><i>Schlussfolgerung: </i></b>Negative Effekte von Psychotherapien sind feststellbar und können mittels Patientenbefragungen und einer systematischen Analyse, via INEP erfasst werden. Die Analyse des Instruments in weiteren klinischen Subpopulationen ist notwendig.
DOI: 10.6084/m9.figshare.5127079
title: Supplementary Material for: Serum Adiponectin Is Associated with Worsened Overall Survival in a Prospective Cohort of Hepatocellular Carcinoma Patients

description: <b><i>Background:</i></b> Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The rise in metabolic syndrome has contributed to this trend. Adipokines, such as adiponectin, are associated with prognosis in several cancers, but have not been well studied in HCC. <b><i>Methods:</i></b> We prospectively enrolled 140 patients with newly diagnosed or recurrent HCC with Child-Pugh (CP) class A or B cirrhosis. We examined associations between serum adipokines, clinicopathological features of HCC, and time to death. We also examined a subset of tumors with available pathology for tissue adiponectin receptor (AR) expression by immunohistochemistry. <b><i>Results:</i></b> The median age of subjects was 62 years; 79% were men, 59% had underlying hepatitis C, and 36% were diabetic. Adiponectin remained a significant predictor of time to death (hazard ratio 1.90; 95% confidence interval 1.05-3.45; p = 0.03) in a multivariable adjusted model that included age, alcohol history, CP class, stage, and serum E-fetoprotein level. Cytoplasmic AR expression (AR1 and AR2) in tumors trended higher in those with higher serum adiponectin levels and in those with diabetes mellitus, but the association was not statistically significant. <b><i>Conclusions:</i></b> In this hypothesis-generating study, we found the serum adiponectin level to be an independent predictor of overall survival in a diverse cohort of HCC patients. <b><i>Impact:</i></b> Understanding how adipokines affect the HCC outcome may help develop novel treatment and prevention strategies. i 2014 S. Karger AG, Basel
DOI: 10.6084/m9.figshare.5127082.v1
title: Supplementary Material for: Patient Knowledge of Antithyroid Drug-Induced Agranulocytosis

description: <b><i>Background:</i></b> Agranulocytosis is a serious side effect of antithyroid drugs. <b><i>Objective:</i></b> To ascertain the knowledge of patients and review the quality of information available on the internet. <b><i>Methods:</i></b> A questionnaire survey was performed for patients receiving antithyroid drugs. Patients attending endocrine clinics who were receiving antithyroid drug treatment (group A, n = 33) were interviewed. A further national cohort of patients (group B, n = 100) treated with antithyroid drugs, participated in an online survey. <b><i>Results:</i></b> 60.9% of responders were not aware of the common symptoms of agranulocytosis. 18.6% had never received any information about side effects. Of the 108 patients who recalled receiving information, 30% rated the quality as ‘poor' or ‘not good at all'. Structured interviews of group A patients revealed that almost half (45.5%, 15/33) had experienced symptoms that could be indicative of agranulocytosis, but only 53.3% (8/15) had a blood count checked. A review of 20 selected patient information internet sites revealed a significant variation in advice given to patients. <b><i>Conclusions:</i></b> Inadequate knowledge about agranulocytosis among patients receiving antithyroid drug treatment is common. The available information on the internet is variable and inconsistent.
DOI: 10.6084/m9.figshare.5127085.v1
title: Supplementary Material for: <b><i>UCH-L1</i></b> S18Y Variant and Risk of Parkinson's Disease in Asian Populations: An Updated Meta-Analysis

description: The ubiquitin carboxy-terminal hydrolase L1 <i>(UCH-L1)</i> gene has been implicated in the etiology of Parkinson's disease (PD). Several studies have evaluated the association between the<i> UCH-L1 </i>S18Y variant and the risk of PD. However, conflicting results have been reported. Therefore, we performed a meta-analysis to explore whether the <i>UCH-L1</i> S18Y variant is associated with susceptibility to PD in Asians. A database search in Web of Science, MEDLINE, Embase and PubMed up to March 2014 identified 10 studies comprising 4,897 PD patients and 4,446 controls in total, which were included in this meta-analysis. In an updated meta-analysis, no significant associations between the S18Y polymorphism and PD in Asians were observed in recessive [p = 0.28, odds ratio (OR) = 1.47, 95% confidence interval (CI): 0.86-1.04] or dominant models (p = 0.46, OR = 0.96, 95% CI: 0.88-1.06). In the subgroup analysis by ethnicity, still no significant association was detected in dominant (for Chinese, OR = 0.97, 95% CI: 0.85-1.10; for Japanese, OR = 0.96, 95% CI: 0.83-1.11) and recessive models (for Chinese, OR = 0.99, 95% CI: 0.88-1.11; for Japanese, OR = 0.89, 95% CI: 0.76-1.04). The results of this meta-analysis suggested that the <i>UCHL-1 </i>S18Y polymorphism was not associated with the risk of PD in Asians. To our knowledge, this is the latest and largest meta-analysis assessing the association of the<i> UCHL-1 </i>S18Y variant with the risk of PD in Asian ancestry.
DOI: 10.6084/m9.figshare.5127088.v1
title: Supplementary Material for: The Study of Breast Milk IGF-1, Leptin, Ghrelin and Adiponectin Levels as Possible Reasons of High Weight Gain in Breast-Fed Infants

description: <b><i>Background:</i></b> Excessive consumption of protein that leads to increased blood levels of insulin-like growth factor-1 (IGF-1) is an important risk factor for high growth velocity and obesity in formula-fed infants. However, it is not clear whether these factors can explain the high growth velocity in breast-fed infants. <b><i>Aim:</i></b> To study the possible links between the growth velocity in breast-fed infants and the levels of protein, IGF-1 and other hormones, which regulate energy homeostasis, in mothers' breast milk. <b><i>Methods:</i></b> We studied 103 mother-infant pairs. Their daily breast milk intake and level of IGF-1, leptin, ghrelin, adiponectin, protein and fat in breast milk were measured at 1, 2 and 3 months of lactation. The infant group was divided into three subgroups of low, normal and high weight gain tertiles. <b><i>Results:</i></b> The breast milk consumed by the infants with high weight gain contained higher levels of IGF-1 than that consumed by those with low weight gain at all periods studied (p = 0.032 at 3 months of lactation), and ghrelin levels were higher at 1 and 2 months and leptin levels at 2 and 3 months of lactation (p &lt; 0.05). A positive correlation was observed between the breast milk IGF-1 level and infant weight gain (r = 0.294, p = 0.043). Total daily breast milk, fat and hormone intake was also higher in the high weight gain group compared to the low weight gain group. <b><i>Conclusion:</i></b> One of the reasons for the high growth velocity in breast-fed infants may be the enhanced levels of the studied hormones in breast milk.
DOI: 10.6084/m9.figshare.5127067
title: Supplementary Material for: Mood and Anxiety Disorders as Early Manifestations of Medical Illness: A Systematic Review

description: <b><i>Background:</i></b> Affective disturbances involving alterations of mood, anxiety and irritability may be early symptoms of medical illnesses. The aim of this paper was to provide a systematic review of the literature with qualitative data synthesis. <b><i>Methods:</i></b> MEDLINE, PsycINFO, EMBASE, Cochrane, and ISI Web of Science were systematically searched from inception to February 2014. Search terms were ‘prodrome/early symptom', combined using the Boolean ‘AND' operator with ‘anxiety/depression/mania/hypomania/irritability/irritable mood/hostility', combined with the Boolean ‘AND' operator with ‘medical illness/medical disorder'. PRISMA guidelines were followed. <b><i>Results:</i></b> A total of 21 studies met the inclusion criteria and were analyzed. Depression was found to be the most common affective prodrome of medical disorders and was consistently reported in Cushing's syndrome, hypothyroidism, hyperparathyroidism, pancreatic and lung cancer, myocardial infarction, Wilson's disease, and AIDS. Mania, anxiety and irritability were less frequent. <b><i>Conclusions:</i></b> Physicians may not pursue medical workup of cases that appear to be psychiatric in nature. They should be alerted that disturbances in mood, anxiety and irritability may antedate the appearance of a medical disorder.
DOI: 10.6084/m9.figshare.5127070
title: Supplementary Material for: Serum Fibroblast Growth Factor 21 Levels Are Inversely Associated with Growth Rates in Infancy

description: <b><i>Background:</i></b> Fibroblast growth factor 21 (FGF21) is a metabolic and growth regulator. <b><i>Aim:</i></b> To investigate the role of FGF21 during growth in infancy. <b><i>Methods:</i></b> Blood samples for FGF21, leptin, insulin and glucose were collected from cord blood obtained from 95 preterm and term newborns (cross-sectional group), and at 6 and 12 months of life in 80 preterm and term infants (longitudinal group). Length and weight were measured at birth, 6 months, and 12 months. <b><i>Results:</i></b> From birth through 12 months of age, preterm infants' linear growth and weight gain were larger than those of term infants, irrespective of birth weight SDS. At birth and at 12 months, there was no difference in FGF21 levels between preterm and term infants; in contrast, at 6 months, serum FGF21 in term infants was significantly higher than that of preterm ones. In the 0-6-month period, in the whole longitudinal group, serum FGF21 was inversely correlated to the length change SDS, and such a significant inverse correlation persisted in the preterm-AGA group in the 6-12-month period. In addition, term infants who experienced length catch-up in the first 6 months of life exhibited lower serum FGF21 levels at 6 months, and those with length catch-up growth between 6 and 12 months had a greater decrease of serum FGF21 level in the same time period. <b><i>Conclusions:</i></b> Our results indicate that FGF21 in infancy is inversely correlated with linear growth rate, thus suggesting that FGF21 is a negative regulator of human growth.
DOI: 10.6084/m9.figshare.5127073
title: Supplementary Material for: Staphylococcal Exotoxins Induce Interleukin 22 in Human Th22 Cells

description: <b><i>Background:</i></b> We have shown previously that T cells from atopic dermatitis (AD) patients produce more IL-22 upon staphylococcal exotoxin stimulation compared to psoriasis patients and healthy controls. The role of staphylococcal exotoxins on polarized memory T helper (Th)22 cells which are enriched in inflamed AD skin remains elusive. Our aim was to investigate IL-22 production in response to staphylococcal enterotoxin B (SEB) and α-toxin stimulation in human memory T cells and polarized Th22 cells. <b><i>Methods:</i></b> IL-22 induction was investigated in human peripheral blood-derived CD4+CD45RO+CD45RA- T cells and polarized Th22 cells after SEB and sublytic α-toxin stimulation in a time-dependent manner at the mRNA and protein (ELISA) levels. <b><i>Results:</i></b> Th22 cells secreted more IL-22 compared to freshly isolated peripheral blood-derived memory T cells. SEB and α-toxin induced IL-22 in memory T cells as well as in Th22 cells. More IL-22 was induced by SEB and α-toxin in freshly isolated peripheral blood memory T cells compared to Th22 cells derived from memory T cells in long-term cell culture without polarization and Th22 cells under Th22-promoting conditions with IL-6 and TNF-α. No differences in IL-22 induction by staphylococcal exotoxins were observed between cells from AD compared to psoriasis patients and healthy controls. <b><i>Conclusions:</i></b> Increased IL-22 secretion can promptly be induced by staphylococcal exotoxins in skin infiltrating CD4+CD45RO+CD45RA- memory T cells and can potentially amplify chronic skin inflammation in AD in the context of bacterial colonization and infection. This should be investigated further in detail in lesional skin of AD and psoriasis patients.
DOI: 10.6084/m9.figshare.5127064
title: Supplementary Material for: The Relationship Between Ultraviolet Light Exposure and Mortality in Dialysis Patients

description: <b><i>Background:</i></b> Emerging data suggest that reduced exposure to ultraviolet (UV) radiation is associated with increased mortality in the general population. To date, the association between UV exposure and mortality in dialysis patients has not been examined. <b><i>Methods:</i></b> We examined the association between UV index, a proxy of UV exposure, and all-cause mortality among 47,286 US dialysis patients (entry period 2001-2006, with follow-up through 2009) from a large national dialysis organization using multivariable Cox regression. The UV index was ascertained by linking individual patients' residential zip codes to National Oceanic and Atmospheric Administration data, and was categorized as low (0-&lt;3), moderate (3-&lt;5), moderate-high (5-&lt;6), high (6-&lt;7), and very-high (≥7). In secondary analyses, we examined the UV index-mortality association within subgroups of age (&lt;65 vs. ≥65 years old), sex, and race (white vs. non-white). <b><i>Results:</i></b> The study population's mean ± SD age was 60 ± 16 and included 46% women and 56% diabetics. Compared to patients residing in moderate-high UV index regions, those residing in high and very-high UV index regions had a lower mortality risk: adjusted HRs 0.84 (95% CI) 0.81-0.88 and 0.83 (95% CI) 0.75-0.91, respectively. A similar inverse association between UV index and mortality was observed across all subgroups, although there was more pronounced reduction in mortality among whites vs. non-whites. <b><i>Conclusion:</i></b> These data suggest that dialysis patients residing in higher UV index regions have lower all-cause mortality compared to those living in moderate-high UV regions. Further studies are needed to determine the mechanisms underlying the UV index-mortality association.
DOI: 10.6084/m9.figshare.5127079.v1
title: Supplementary Material for: Serum Adiponectin Is Associated with Worsened Overall Survival in a Prospective Cohort of Hepatocellular Carcinoma Patients

description: <b><i>Background:</i></b> Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The rise in metabolic syndrome has contributed to this trend. Adipokines, such as adiponectin, are associated with prognosis in several cancers, but have not been well studied in HCC. <b><i>Methods:</i></b> We prospectively enrolled 140 patients with newly diagnosed or recurrent HCC with Child-Pugh (CP) class A or B cirrhosis. We examined associations between serum adipokines, clinicopathological features of HCC, and time to death. We also examined a subset of tumors with available pathology for tissue adiponectin receptor (AR) expression by immunohistochemistry. <b><i>Results:</i></b> The median age of subjects was 62 years; 79% were men, 59% had underlying hepatitis C, and 36% were diabetic. Adiponectin remained a significant predictor of time to death (hazard ratio 1.90; 95% confidence interval 1.05-3.45; p = 0.03) in a multivariable adjusted model that included age, alcohol history, CP class, stage, and serum E-fetoprotein level. Cytoplasmic AR expression (AR1 and AR2) in tumors trended higher in those with higher serum adiponectin levels and in those with diabetes mellitus, but the association was not statistically significant. <b><i>Conclusions:</i></b> In this hypothesis-generating study, we found the serum adiponectin level to be an independent predictor of overall survival in a diverse cohort of HCC patients. <b><i>Impact:</i></b> Understanding how adipokines affect the HCC outcome may help develop novel treatment and prevention strategies. i 2014 S. Karger AG, Basel
DOI: 10.6084/m9.figshare.5127049
title: Supplementary Material for: Body Mass Index and Mortality in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis

description: <b><i>Background:</i></b> A higher body mass index (BMI) seems to be linked to survival advantage in maintenance hemodialysis patients. However, it is uncertain if this ‘obesity survival paradox' is also observed in kidney transplant recipients. Hence, we systematically reviewed the literature on the impact of pre-transplantation BMI on all-cause mortality in this population. <b><i>Methods:</i></b> We searched MEDLINE, EMBASE, Web of Science, CINAHL, and Cochrane CENTRAL for relevant studies up to July 2013. Two investigators independently selected the studies using predefined criteria, abstracted the data from the included studies, and independently assessed each study's quality using the Newcastle-Ottawa Quality Assessment Scale. In addition to the qualitative synthesis, we quantitatively pooled the results of the studies with clinical, methodological, and statistical homogeneity. <b><i>Results:</i></b> We screened 7,123 records, from which we included 11 studies (with a total of 305,392 participants) in this systematic review and 4 studies in the meta-analyses. In the only study that included children, obesity was linked to higher mortality in children of 6-12 years old. For adults, our meta-analyses indicated that compared to normal BMI, underweight [Hazard Ratio (HR): 1.09; 95% Confidence Interval (CI): 1.02-1.20], overweight (HR: 1.07; 95% CI: 1.04-1.12), and obese (HR: 1.20; 95% CI: 1.14-1.23) levels of BMI were associated with higher mortality. <b><i>Conclusion:</i></b> The presence of the obesity survival paradox is unlikely in kidney transplant recipients since both extremes of pre-transplantation BMI are linked to higher mortality in this population.
DOI: 10.6084/m9.figshare.5127052
title: Supplementary Material for: Neurally Adjusted Ventilatory Assist in Preterm Neonates with Acute Respiratory Failure

description: <b><i>Background:</i></b> Neurally adjusted ventilatory assist (NAVA) is a novel mode of ventilation that has been demonstrated to improve infant-ventilator interaction, compared to the conventional modes in retrospective and short-term studies. <b><i>Objectives:</i></b> To prospectively evaluate the physiologic effects of NAVA in comparison with pressure-regulated volume control (PRVC) in two nonrandomized 12-hour periods. <b><i>Methods:</i></b> We studied 14 consecutive intubated preterm neonates receiving mechanical ventilation for acute respiratory failure. Peak airway pressure (Paw<sub>peak</sub>), diaphragm electrical activity (EAdi), tidal volume (V<sub>T</sub>), mechanical (RR<sub>mec</sub>) and neural (RR<sub>neu</sub>) respiratory rates, neural apneas, and the capillary arterialized blood gases were measured. The RR<sub>mec</sub>-to-RR<sub>neu</sub> ratio (MNR) and the asynchrony index were also calculated. The amount of fentanyl administered was recorded. <b><i>Results:</i></b> Paw<sub>peak</sub> and V<sub>T</sub> were greater in PRVC (p &lt; 0.01). Blood gases and RR<sub>mec</sub> were not different between modes, while RR<sub>neu</sub> and the EAdi swings were greater in NAVA (p = 0.02 and p &lt; 0.001, respectively). MNR and the asynchrony index were remarkably lower in NAVA than in PRVC (p = 0.03 and p &lt; 0.001, respectively). 1,841 neural apneas were observed during PRVC, with none in NAVA. Less fentanyl was administered during NAVA, as opposed to PRVC (p &lt; 0.01). <b><i>Conclusions:</i></b> In acutely ill preterm neonates, NAVA can be safely and efficiently applied for 12 consecutive hours. Compared to PRVC, NAVA is well tolerated with fewer sedatives.
DOI: 10.6084/m9.figshare.5127061
title: Supplementary Material for: Heparin Use in Hemodialysis Patients following Gastrointestinal Bleeding

description: <b><i>Background:</i></b> Heparin is commonly given during hemodialysis (HD). Patients undergoing HD have a high rate of gastrointestinal bleeding (GIB). It is unclear whether or when it is safe to give heparin after acute GIB. We describe the patterns and safety of heparin use with outpatient HD following an acute GIB. <b><i>Methods:</i></b> We identified patients aged ≥67 who, from 2004-2008, experienced GIB requiring hospitalization within 2 days of receiving maintenance HD with heparin. We used Cox regression to estimate the risk of recurrent GIB and death associated with receiving heparin the day they resumed outpatient HD post-GIB. <b><i>Results:</i></b> Of the 1,342 patients who had GIB, 1,158 (86%) received heparin at a median dose of 4,000 units with their first outpatient HD session after discharge from GIB. On average, their post-GIB doses were slightly lower than their pre-GIB doses (mean change: -214 ± 3,266 units, p &lt; 0.02). However, only 27% of patients had a decrease in their dose, while 21% had their dose increased. We did not find an increased risk of death or recurrent GIB associated with using heparin post-GIB (HR; 95% confidence interval (CI), for death: 1.01; 0.69-1.48; for recurrent GIB: 0.78; 0.39-1.57). <b><i>Conclusions:</i></b> The vast majority of these high-risk patients received heparin on the very first day they resumed outpatient HD post-GIB, and the majority at unchanged doses to those received pre-GIB. Even if the practice was not associated with increased risks of death or re-bleeding, it highlights an area for possible system-based improvement to the care for patients on HD.